Search

Policy on double awarding

We want to support as many young investigators and clinicians as possible in their career development. For this reason, we do not allow ‘double awarding.

Read more

Policy on double awarding

We want to support as many young investigators and clinicians as possible in their career development. For this reason, we do not allow ‘double awarding.

Read more

Policy on double awarding

We want to support as many young investigators and clinicians as possible in their career development. For this reason, we do not allow ‘double awarding.

Read more

Policy on double awarding

We want to support as many young investigators and clinicians as possible in their career development. For this reason, we do not allow ‘double awarding.

Read more

Breakthrough results in European multicenter trial on acute promyelocytic leukemia (APL): no more chemotherapy?

APL is a rare, yet aggressive, subtype of acute myeloid leukemia (AML) characterized by a maturation arrest of white blood cell precursors in the marrow, leading to a shortage of normal white cells and platelets in the blood, which is…

Read more

New EU In Vitro Diagnostic medical devices Regulation (IVDR) comes into effect

On May 26, 2022, the new EU In Vitro Diagnostic medical devices Regulation (IVDR) came into effect, mandating stricter and more comprehensive certification and testing protocols for in vitro diagnostic medical devices.

Read more

News

New EU In Vitro Diagnostic medical devices Regulation (IVDR) comes into effect

On May 26, 2022, the new EU In Vitro Diagnostic medical devices Regulation (IVDR) came into effect, mandating stricter and more comprehensive certification and testing protocols for in vitro…

Read more

Pivotal Ruxolitinib Data Shows Promise for Patients with PV.

 

Polycythemia vera (PV) is a chronic, incurable blood cancer with limited treatment options. If uncontrolled, PV can cause serious cardiovascular complications, such as stroke and heart attack.

Read more

Research trainings

Old ways won't open new doors. Via non-pecuniary awards, EHA strives to accelerate the careers of promising post-docs in translational or clinical research.

Read more